eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Share:
Share:
more
 
 
abstract:
Case report

Very high-risk locally advanced prostate ductal adenocarcinoma cured using low-dose-rate brachytherapy, with seminal vesicle implantation in combination with external beam radiotherapy at a biologically effective dose ≥ 220 Gy: two case reports with a long-term follow-up

Keisei Okamoto
1, 2

1.
Department of Brachytherapy for Prostate Cancer, Shiga University of Medical Science, Shiga, Japan
2.
Department of Urology, Uji Hospital, Uji City, Kyoto, Japan
J Contemp Brachytherapy 2022; 14
Online publish date: 2022/09/21
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
Prostate ductal adenocarcinoma (PDA) is an aggressive, rare variant of histologic sub-type of prostate cancer. Patients with PDA present with more aggressive clinical features and have a poorer prognosis than patients with acinar adenocarcinoma. So far, an optimal treatment for PDA has yet to be established. Furthermore, the effectiveness of low-dose-rate (LDR) brachytherapy for PDA has not been reported previously.

Case presentation
In this paper, we present two case reports on very high-risk locally advanced PDA, in which patients were successfully treated with LDR brachytherapy, with seminal vesicle implantation in combination with external beam radiotherapy (EBRT) at a biologically effective dose (BED) ≥ 220 Gy and short-term androgen deprivation therapy (ADT). There was no grade 2 genitourinary (GU) and gastrointestinal (GI) toxicities during follow-up, and no evidence of hematuria nor rectal bleeding during follow-up. The patients stay healthy without biochemical failure and without bowel or urinary difficulties at 11.5 years and 8 years, respectively.

Conclusions
High-BED LDR-based radiotherapy in combination with EBRT (BED ≥ 220 Gy) may be an ideal treatment for very high-risk locally advanced PDA patients.

keywords:

locally advanced prostate cancer, low-dose-rate (LDR) brachytherapy, complete cure, biologically effective dose (BED), prostate ductal adenocarcinoma (PDA), very high-risk prostate cancer

 
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.